AnticoagulantAcetylsalicylic acidClass of Antiplatelet AgentsStatinsClopidogrelAnticoagulants and antiplateletVitamin K antagonistsCoronaryPatientsTherapyCardiovascularSecondary preventionMedicationsDrugsPreventionInhibitorTicagrelorExertsMyocardial infarctionClinicalCyclooxygenase inhibitorsWidelyInhibitTreatmentThrombolyticAbstractMonotherapyRiskEffectDrugAntithrombotic agents
Anticoagulant9
- 2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Solution Set Oversight Committee. (acc.org)
- When combined with an anticoagulant, clopidogrel is the recommended antiplatelet agent for most patients. (acc.org)
- Which is more beneficial as an antiplatelet/anticoagulant? (ironwillreport.com)
- as a potent anticoagulant agent in preventing heart attacks, stroke, and atherothrombotic diseases? (ironwillreport.com)
- Antiplatelet/anticoagulant effects of NK Low-dose aspirin (85-100mg daily), as a potent anticoagulant agent, is widely used for the prevention of heart attacks, stroke, and atherothrombotic diseases. (ironwillreport.com)
- No other antiplatelet or anticoagulant agents were permitted. (medscape.com)
- 60 years, receiving anticoagulant or antiplatelet medicinal products, or prior history of major bleeding events. (drugs.com)
- We searched for studies, giving preference to randomised controlled trials (studies where participants are randomly assigned to one of two or more treatment groups), that evaluated prophylactic anticoagulants given to people with COVID-19 in the outpatient setting, compared with placebo or no treatment, a different dose of the same anticoagulant, or antiplatelet agents. (cochrane.org)
- Five studies compared anticoagulants versus placebo or no treatment, and one study also compared a prophylactic anticoagulant with a different dose of the same anticoagulant as well as versus antiplatelet agents. (cochrane.org)
Acetylsalicylic acid3
- Antiplatelet agents, such as acetylsalicylic acid, have been shown to effectively reduce thrombotic events in other diseases: they could influence the course of COVID-19 in general. (qxmd.com)
- A total of 2109 participants were analysed in the antiplatelet arm (treated with acetylsalicylic acid) and 2100 participants in the control arm. (qxmd.com)
- Results: The results indicated that among antithrombotic and antiplatelet agents taken by patients the most often used were: acetylsalicylic acid (140 patients) and clopidogrel (64 patients), while acenocoumarol derivatives were taken by 25 patients. (edu.pl)
Class of Antiplatelet Agents1
- The latest class of antiplatelet agents, called cyclo-pentyl-triazolo-pyrimidines, includes ticagrelor and cangrelor. (jabfm.org)
Statins2
- Pharmacotherapeutic strategies that affect the risk factor profile, such as the administration of statins for low-density lipoprotein (LDL) reduction or the administration of agents that alter atherosclerotic plaque, are of paramount importance. (medscape.com)
- These patients will have been taking statins, antiplatelet agents, and if they have atrial fibrillation they will be on anticoagulants. (medscape.com)
Clopidogrel9
- The most prescribed agents are aspirin and clopidogrel, two cornerstones of the antiplatelet therapy [ 7 - 9 ]. (hindawi.com)
- The addition of prasugrel to aspirin for dual antiplatelet therapy has been shown to reduce the ischemic outcomes compared with clopidogrel and aspirin in combination. (jabfm.org)
- Clopidogrel is the most widely prescribed P2Y12 inhibitor in the world despite the development of newer and more potent agents. (ecrjournal.com)
- In the recently published Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) trial, a guided de-escalation strategy from prasugrel to clopidogrel after an acute coronary syndrome (ACS), monitored by a platelet reactivity test, was non-inferior to conventional strategy with prasugrel. (ecrjournal.com)
- 8 Given the uncertainty of evidence and the high cost of the alternative agents to clopidogrel and the cost of the platelet reactivity tests, local cost-effectiveness analyses are necessary before widely adopting these strategies. (ecrjournal.com)
- Often a combination of aspirin plus an ADP/P2Y inhibitor (such as clopidogrel, prasugrel, ticagrelor, or another) is used to obtain greater effectiveness than with either agent alone. (wikipedia.org)
- Classes of antiplatelet drugs include: Adenosine diphosphate (ADP) receptor inhibitors Cangrelor (Kengreal) Clopidogrel (Plavix) Prasugrel (Effient) Ticagrelor (Brilinta) Ticlopidine (Ticlid) Adenosine reuptake inhibitors Dipyridamole (Persantine) Glycoprotein IIB/IIIA inhibitors (intravenous use only) Abciximab (ReoPro) Eptifibatide (Integrilin) Tirofiban (Aggrastat) Irreversible cyclooxygenase inhibitors Aspirin Triflusal (Disgren) Phosphodiesterase inhibitors Cilostazol (Pletaal) Protease-activated receptor-1 antagonists (which inhibit the protease-activated receptor 1 a.k.a. (wikipedia.org)
- The recent Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance trial, which evaluated the effects of clopidogrel plus aspirin compared with aspirin alone, seems to support the use of dual antiplatelet therapy in secondary prevention, but suggests that it may not be more effective than aspirin alone in primary prevention. (wustl.edu)
- The expected antiplatelet effect of a 600 mg loading dose of clopidogrel was blocked when clopidogrel was administered during a cangrelor infusion. (medscape.com)
Anticoagulants and antiplatelet6
- This poses a problem particularly in light of the pervasive use of anticoagulants and antiplatelet agents for this population, both of which increase the bleeding risk. (jefferson.edu)
- Anticoagulants and antiplatelet agents are used for a variety of conditions, including deep venous thrombosis, atrial fibrillation, pulmonary embolism and coronary artery disease. (jefferson.edu)
- The use of anticoagulants and antiplatelet agents for prevention of cardiovascular and cerebrovascular events is irrefutable, but little literature has touched on its effects on morbidity and mortality in those with traumatic brain injury. (jefferson.edu)
- This article summarizes the current literature on the pre-TBI use of anticoagulants and antiplatelet agents and the associated morbidity and mortality. (jefferson.edu)
- What Are Anticoagulants and Antiplatelet Agents? (medlineplus.gov)
- In October 2021, ISTH assembled an international panel of content experts, patient representatives, and a methodologist to develop recommendations on anticoagulants and antiplatelet agents for patients with COVID-19 in different clinical settings. (nih.gov)
Vitamin K antagonists2
- The association between preceding treatment with antiplatelet agents (APs), vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) and mortality after intracerebral hemorrhage (ICH) remains unclear. (univaq.it)
- Cosmi B, Martini E, Sandri S, Lunardelli ML, Gorgoglione FL, De Laurenzo A, Grandone E. Direct Oral Anticoagulants in Comparison with Vitamin K Antagonists and Antiplatelet Agents on Timing and Outcomes in Hip Fracture Surgery Patients Older than 75: The ORTHO-GER-DOAC Study [abstract]. (isth.org)
Coronary10
- In the large TRA-2P study of more than 26,000 patients with MI, ischemic stroke, or documented peripheral vascular disease, the novel antiplatelet agent vorapaxar significantly reduced the primary endpoint of CV death, MI, stroke or urgent coronary revascularization. (cardiobrief.org)
- Antiplatelet agents are medications that are mainly used to treat and prevent thromboembolic events like ischemic stroke , transient ischemic attack , and coronary artery disease or myocardial infarction , as well as in clients who underwent cardiac valve replacement or coronary angioplasty , or those with peripheral artery disease . (osmosis.org)
- Coronary artery disease pathophysiology and platelet physiology are summarized, and the use of antiplatelet drugs in coronary artery disease is reviewed. (elsevierpure.com)
- Aspirin alone or in combination with a thienopyridine (dual antiplatelet therapy) reduces the risk of coronary ischemic events in patients with ACS. (jabfm.org)
- Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis. (ox.ac.uk)
- Antiplatelet drugs provide first-line antithrombotic therapy for the management of acute ischemic syndromes (both coronary and cerebrovascular) and for the prevention of their recurrence. (ox.ac.uk)
- The aim of this consensus document is to review the evidence for the efficacy and safety of antiplatelet drugs, and to provide practicing cardiologists with an updated instrument to guide their choice of the most appropriate antiplatelet strategy for the individual patient presenting with different clinical manifestations of coronary atherothrombosis, in light of comorbidities and/or interventional procedures. (ox.ac.uk)
- Patients who require the use of antiplatelet drugs are: stroke with or without atrial fibrillation, any heart surgery (especially prosthetic replacement heart valve), Coronary Heart Disease such as stable angina, unstable angina and heart attack, patients with coronary stent, Peripheral Vascular Disease/Peripheral Arterial Disease and apical/ventricular/mural thrombus. (wikipedia.org)
- Patients using antiplatelet therapy for primary cardiovascular disease prevention or >12 months from the most recent PCI or acute coronary syndrome can be treated with anticoagulation monotherapy. (acc.org)
- Dual antiplatelet therapy (DAPT) consisting of aspirin plus a P2Y 12 inhibitor has been the standard of care to prevent thrombotic events in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). (medscape.com)
Patients27
- Patients The interaction of antiplatelet therapy with the prediction variables of main decision aids was analysed in 14 288 consecutive adolescent and adult subjects with mild head injury. (bmj.com)
- Outcomes in Traumatic Brain Injury Patients on Preinjury Anticoagulation and Antiplatelet Agents" by Sandra Ho, BA, MHS, 4th year medical student, Vismay Thakkar, MBBS et al. (jefferson.edu)
- Antiplatelet therapy should not be used in patients at high risk for bleeding. (elsevierpure.com)
- Antiplatelet therapy has been shown to reduce mortality rate by reducing the risk of fatal strokes, fatal myocardial infarctions, and vascular death in patients with a history of transient ischemic attacks. (medscape.com)
- The role of chronic administration of antiplatelet drugs in primary prevention of arterial vascular events is known to be less clear than in secondary prevention, and, also in diabetic patients, the decision to give primary prophylaxis should be taken on an individual-patient basis, after a careful evaluation of the balance between the expected benefits and the risk of major bleedings. (hindawi.com)
- This paper reviews the role of currently available antiplatelet drugs in primary and secondary prevention of vascular events in diabetic patients and the limitations of these drugs, and it discusses the role of novel and more potent antiplatelets and of new agents currently under clinical development. (hindawi.com)
- The role of novel and more potent antiplatelet strategies, currently under clinical development, seems attractive in diabetic patients. (hindawi.com)
- However, being a more potent antiplatelet agent, prasugrel increases the risk of bleeding, especially in those patients who are at a higher risk of bleeding complications. (jabfm.org)
- Aspirin, which exerts its antiplatelet effects by inhibiting thromboxane A2 production, has been the mainstay of antiplatelet therapy in patients with ACS. (jabfm.org)
- Antiplatelet agents are the cornerstone of secondary prevention for patients who present with an ischemic stroke or transient ischemic attack (TIA). (healthplexus.net)
- The aim of this multicenter, prospective cohort study was to assess the risk for death after ICH in consecutive patients who were on treatment with APs, VKAs, DOACs, or no antithrombotic agent. (univaq.it)
- Crude death rate was higher in patients on antithrombotics as compared to patients receiving no antithrombotic agent. (univaq.it)
- Dual antiplatelet therapy has been found to significantly reduce rates of heart attacks, strokes, and overall cardiovascular death, but is not used in low-risk patients because it significantly increases the risks of major bleeding. (wikipedia.org)
- In general, the use of "triple therapy" (dual antiplatelet therapy plus anticoagulation) is not recommended for most patients due to an increased risk of bleeding. (acc.org)
- For patients taking ≥2 antithrombotic agents, starting or continuing a proton pump inhibitor and avoiding other anti-inflammatory medications should be employed to reduce gastrointestinal bleeding risk. (acc.org)
- For patients on antiplatelet therapy who develop new AF, management depends on the indication for antiplatelet therapy. (acc.org)
- For patients on antiplatelet therapy who develop a new VTE event, use of anticoagulation plus single antiplatelet medication is generally recommended. (acc.org)
- Role of antiplatelet agents in the primary and secondary prevention of atherothrombotic events in high risk-patients. (wustl.edu)
- The main aim of the study was to assess the awareness and knowledge of side effects and possible complications in patients taking antithrombotic and antiplatelet agents due to cardiological recommendations. (edu.pl)
- Parenteral anticoagulation, in addition to antiplatelet therapy, is recommended for all patients with NSTE-ACS regardless of initial treatment strategy. (aafp.org)
- A new pilot study suggests that aspirin can be discontinued on the day after the PCI, and colchicine , an anti-inflammatory agent, could be added to reduce the risk for ischemic events in these patients, while mitigating the increased bleeding risk associated with aspirin. (medscape.com)
- It turned out that one of the patients had not been adherent with antiplatelet medications. (medscape.com)
- Antithrombotic agents reduce risk of thromboembolism in severely ill patients. (nih.gov)
- Weak recommendations favored (a) sulodexide in non-hospitalized patients, (b) adding an antiplatelet agent to prophylactic LMWH/UFH in select critically ill, and (c) prophylactic rivaroxaban for select patients after discharge (all COR 2b). (nih.gov)
- These results suggest that the use of alum as an oral antiplatelet drug could be explored further, taking into account possible side-effects especially in renal compromised patients. (who.int)
- Ces résultats semblent indiquer que l'utilisation de l'alun en tant qu'antiplaquettaire oral pourrait faire l'objet d'études complémentaires, en tenant compte des effets secondaires éventuels notamment chez les patients dont la fonction rénale est altérée. (who.int)
- Preoperative patients in cardiac surgery must provide an adequate standard of oral health, without the presence of focal dental infections or triggering infectious foci in the oral cavity since the mouth may be the main gateway-causing microorganisms of Infective Endocarditis (IE) 2 , a disease in which infectious agents colonize endocardial surfaces, producing inflammation and damage 3 . (bvsalud.org)
Therapy17
- Therapy with lipid-lowering agents should be a component of multiple risk factor intervention and is indicated in primary prevention as an adjunct to diet therapy when the response to a diet restricted in saturated fat and cholesterol has been inadequate. (medscape.com)
- 2 Therefore, antiplatelet therapy is indispensible in the early and long-term management of ACS. (jabfm.org)
- However, suboptimal clinical outcomes with aspirin monotherapy resulted in the use of dual antiplatelet therapy with the addition of thienopyridines. (jabfm.org)
- The antiplatelet action of both of these drugs is reversible within hours of discontinuation of therapy. (jabfm.org)
- This led to the introduction of the third-generation thienopyridine prasugrel for dual antiplatelet therapy for ACS management. (jabfm.org)
- Similarly, in the Assessment by a Double Randomization of a Conventional Antiplatelet Strategy versus a Monitoring-guided Strategy for Drug-Eluting Stent Implantation and of Treatment Interruption versus Continuation One Year after Stenting (ARTIC) trial, a platelet-function monitoring strategy, coupled with adequate anti-platelet therapy adjustments, led to lower platelet reactivity, without any significant difference in clinical endpoints. (ecrjournal.com)
- Antiplatelet therapy with one or more of these drugs decreases the ability of blood clots to form by interfering with the platelet activation process in primary hemostasis. (wikipedia.org)
- More severe and complicated cases are treated with dual antiplatelet therapy, or in some cases triple therapy that includes direct oral anticoagulants. (wikipedia.org)
- This is known as "dual antiplatelet therapy" (or DAPT). (wikipedia.org)
- Treatment of established arterial thrombosis includes the use of antiplatelet drugs and thrombolytic therapy. (wikipedia.org)
- 3 classes: Murine-human chimeric antibodies (e.g., abciximab) Synthetic non-peptides (e.g., tirofiban) Synthetic peptides (e.g., eptifibatide) Antiplatelet therapy may increase the risk of a bleed during surgery, however, stopping therapy may increase the risk of other thrombotic problems including myocardial infarction. (wikipedia.org)
- and (4) new or recurrent VTE requiring anticoagulation in a patient already on antiplatelet therapy for CAD. (acc.org)
- If long-term/indefinite anticoagulation is required, then use of standard treatment doses of anticoagulation plus P2Y 12 inhibitor antiplatelet therapy are recommended following PCI. (acc.org)
- Therefore, antiplatelet therapy is an effective treatment choice for secondary prevention. (wustl.edu)
- However, data conflict regarding the efficacy of antiplatelet therapy for primary prevention. (wustl.edu)
- The Mono Antiplatelet and Colchicine Therapy (MACT) single-arm, open-label proof-of-concept study was designed to investigate this approach. (medscape.com)
- This issue of Interventional Cardiology Clinics, edited by Drs. Dominick Angiolillo and Matthew Price, will focus on Antiplatelet and Anticoagulation Therapy in PCI. (elsevier.ca)
Cardiovascular4
- For secondary - after initial infarction - prevention of cardiovascular complications, the administration of aspirin and other antiplatelet agents has consistently decreased the rate of nonfatal myocardial infarction, overall mortality, or both. (elsevierpure.com)
- Antiplatelet agents are effective in primary and secondary prevention of arterial thrombosis (cardiovascular events, ischaemic stroke, and peripheral arterial occlusive disease). (hindawi.com)
- Large clinical trials have shown that antiplatelet agents are effective in the prevention of recurrent cardiovascular events in diabetes. (hindawi.com)
- 6 The atherosclerotic cardiovascular disease risk estimator is available online and in mobile app format at http://my.americanheart.org/cvrisk calculator and at http://www.cardiosource.org/en/Science-And-Quality/Practice-Guidelines-and-Quality-Standards/2013-Prevention-Guideline-Tools.aspx . (aafp.org)
Secondary prevention4
- The clear answer as to whether one or two antiplatelet agents are better for the secondary prevention of ischemic stroke events in older adults depends upon the combination of agents, as well as the monotherapy comparator. (healthplexus.net)
- Antiplatelet drugs are widely used in primary and secondary prevention of thrombotic disease, especially myocardial infarction and ischemic stroke. (wikipedia.org)
- If the dose of anticoagulation is reduced (e.g., "half-dose DOAC" for VTE secondary prevention), then continued use of a single antiplatelet medication (e.g., aspirin) is indicated long-term. (acc.org)
- Current treatment guidelines suggest the use of a combination of these two agents for secondary prevention where appropriate. (wustl.edu)
Medications4
- Now, antiplatelet medications act by preventing the activation of platelets to form a blood clot. (osmosis.org)
- Based on their mechanism of action, antiplatelet medications can be divided into four groups. (osmosis.org)
- Antiplatelet medications are one of the primary recommendations for treatment of both stable and unstable ischemic heart disease. (wikipedia.org)
- When used in combination with antiplatelet medications, dosing of DOAC medications usually follows the Food and Drug Administration guidance for stroke prevention in AF or treatment of VTE. (acc.org)
Drugs8
- Antiplatelet drugs were recorded in 10% of the entire cohort (24.7% in the group over 65 years). (bmj.com)
- Interpretation Antiplatelet drugs need to be considered in future prediction models on mild head injury, considering their increasing use and progressive ageing of the trauma population. (bmj.com)
- Available antiplatelet agents, such as cyclooxygenase-1 (COX-1) inhibitors (aspirin), ADP P2Y 12 receptor antagonists, and GP IIb/IIIa receptor inhibitors, are effective and save in the treatment and prevention of thrombotic events, these drugs interfere with the platelet activation process, including adhesion, release, and aggregation. (hindawi.com)
- Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (online-medical-dictionary.org)
- Antiplatelet drugs can reversibly or irreversibly inhibit the process involved in platelet activation resulting in decreased tendency of platelets to adhere to one another and to damaged blood vessels' endothelium. (wikipedia.org)
- Antiplatelet drugs alter the platelet activation at the site of vascular damage crucial to the development of arterial thrombosis. (wikipedia.org)
- Antiplatelet drugs, except for low-dose aspirin (=81 mg qDay), during the first 3 months of treatment are contraindicated. (medscape.com)
- Antiplatelet and antithrombotic drugs, which stop clots from forming, are used routinely. (msdmanuals.com)
Prevention2
- Ischemic Stroke Prevention: Are Two Antiplatelet Agents Better than One in Older Adults? (healthplexus.net)
- In 2019, the Executive Guideline Steering Group (GSG) for the World Health Organization (WHO) maternal and perinatal health recommendations prioritized updating the then current WHO recommendations on antiplatelet agents for the prevention of pre-eclampsia. (bvsalud.org)
Inhibitor2
- The antiplatelet effect of the inorganic salt sodium tungstate (Na2O4W), a protein tyrosine phosphatase 1B (PTP1B) inhibitor, has been investigated in this study. (redheracles.net)
- An antiplatelet drug (antiaggregant), also known as a platelet agglutination inhibitor or platelet aggregation inhibitor, is a member of a class of pharmaceuticals that decrease platelet aggregation and inhibit thrombus formation. (wikipedia.org)
Ticagrelor3
- Recently, the antiplatelet drug ticagrelor has been reported to have promising antibacterial properties. (utp.edu.co)
- In this paper we discuss a new potential antimicrobial agent, ticagrelor. (utp.edu.co)
- Lancellotti P, Musumeci L, Jacques N, Servais L, Goffin E, Pirotte B, Oury C. Antibacterial Activity of Ticagrelor in Conventional Antiplatelet Dosages Against Antibiotic-Resistant Gram-Positive Bacteria. (utp.edu.co)
Exerts1
- Aspirin exerts its antiplatelet action by inhibiting cyclooxygenase (COX) and subsequently reducing the synthesis of thrombogenic thromboxane A2 (TXA2) in platelets. (ironwillreport.com)
Myocardial infarction1
- Simons M. Antiplatelet agents in unstable angina and acute non-ST elevation myocardial infarction [Internet]. (bvs.br)
Clinical2
- 4 Test for both platelet reactivity and the CYP2C19 genetic variant are currently available, and have the theoretical potential to help clinicians to better choose the anti-platelet agent to be used, but the clinical evidence behind their use is still limited, preventing guidelines from routinely recommending these tests. (ecrjournal.com)
- In case further clinical studies confirm our findings, these may be repurposed as adjuvant agents. (lu.se)
Cyclooxygenase inhibitors1
- A total of 8964 participants were analysed in the antiplatelet arm (either with cyclooxygenase inhibitors or P2Y12 inhibitors) and 8577 participants in the control arm. (qxmd.com)
Widely2
- The utility of evaluating platelet reactivity to tailor antiplatelet strategies has been widely studied, with disappointing findings. (ecrjournal.com)
- Introduction: Nowadays, antithrombotic and antiplatelet agents are widely used in cardiology. (edu.pl)
Inhibit1
- These agents inhibit platelet function by blocking cyclooxygenase and subsequent aggregation. (medscape.com)
Treatment5
- Antiplatelet treatment compared with anticoagulation treatment for cervical artery dissection (CADISS): a randomised trial. (medscape.com)
- Background The effect of pre-injury antiplatelet treatment in the risk of intracranial lesions in subjects after mild head injury (Glasgow Coma Scale (GCS) 14-15) is uncertain. (bmj.com)
- Antiplatelet agents for the treatment of adults with COVID-19. (qxmd.com)
- We included randomised controlled trials (RCTs) evaluating antiplatelet agents for the treatment of COVID-19 in adults with COVID-19, irrespective of disease severity, gender or ethnicity. (qxmd.com)
- HA371 trade name] is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV) infection in adults, adolescents and children. (who.int)
Thrombolytic1
- To this point, there have been no reports of the use of thrombolytic agents such as tissue thromboplastin activator in spinal cord infarction. (medscape.com)
Abstract1
- ABSTRACT Traditionally known as a haemostatic agent, alum shows a paradoxical effect of increased prothrombin and partial thromboplastin times. (who.int)
Monotherapy1
Risk1
- Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (nih.gov)
Effect2
- Personalised Approaches to Improving the Effect of Anti-platelet Agents: Where Do We Stand? (ecrjournal.com)
- Hannachi N, Grac L, Baudoin JP, Fournier PE, Habib G, Camoin-Jau L. Effect of antiplatelet agents on platelet antistaphylococcal capacity: An in vitro study. (utp.edu.co)
Drug4
- The Washington Manual , www.unboundmedicine.com/washingtonmanual/view/Davis-Drug-Guide/50924/all/antiplatelet_agents. (unboundmedicine.com)
- The number of deaths caused by drug-resistant bacteria is expected to increase in the future, and there is a need to develop new antimicrobial agents. (utp.edu.co)
- DOACs were associated with a statistically significant longer mean time to surgery (83.5 h) than VKA (59 h) or antiplatelet agents (45 h) or no antithrombotic drug (37 h) (p=0.001). (isth.org)
- DOACS were associated with higher mean total blood loss (1532 ml) when compared with VKA (1343 ml) or antiplatelet agents (1287 ml) or no antithrombotic drug (1105 ml) (p=0.007). (isth.org)